Add To Watchlist
Share URL
About The Company
Description
AbCellera Biologics Inc.
Read More
Overview
Value
48
Growth
52
Health
72
Management
16
Analyst Opinion
69
Total
51
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Has strong financial health
- Price-to-earnings ratio of 13.3 is lower than the market average (19.6x)
- Low preportion of income is paid as dividend
Risk Factors
- Earnings are negative
- There is a history of diluting shareholders
- No margin of safety at their current market price 0
Latest News

7 Stocks to Bet On if You Want to Be Richer Than Elon Musk
InvestorPlace | 20:26 Wed 22 Mar 2023
Read More →

AbCellera Biologics Inc (ABCL) Q4 2022 Earnings Call Transcript
Seeking Alpha | 00:47 Wed 22 Feb 2023
Read More →

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research | 23:49 Tue 21 Feb 2023
Read More →

The 7 Most Undervalued Biotech Stocks to Buy in February 2023
InvestorPlace | 19:19 Thu 2 Feb 2023
Read More →
Market Peers
ABCL
Key Figures
PE Ratio (TTM)
13.34
Margin Of Safety (DCF)
-16.30%
Revenue Growth (5 Year Average)
21.08%
Ratings Consensus
Buy
Share Buybacks
-2.37%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
48
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 5.4 USD ✘
Current Price: 7.4 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
13.34x
Free Cashflow Yeild
9.61%
PE/Earnings Growth
N/A
Price/Book
1.73x
Growth
Growth Score
52
- ✔ 5 Year Average Revenue growth of 21.08% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 14.83% is higher than the market average (12.35%)
- ✘ 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
21.08%
Earnings Growth
N/A
Cashflow Growth
14.83%
Health
Health Score
72
Altman Z Score
6.16
Piostroski Score
6.00
Debt/Equity
0.07x
Current Assets/Liabilities
8.67x
Free Cashflow/Total Debt
0.23x
Debt/Capital
0.08x
Management
Management Score
16
Average Buybacks/Dilution
-2.37%
Recent Buybacks/Dilution
0.83%
5 Year Price Volitility
62.49%
Return On Assets
-1.96%
Return On Capital Employed
-0.04%
Return On Equity
-2.44%
Return On Free Cashflow
21.33%
Return On Investments
-5.27%
Analysts
Analyst Opinion
69
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
AbCellera Biologics Inc.
Currency
USD
Beta
-0.428002
Vol Avg
2041675
Ceo
Dr. Carl L. Hansen
Cik
0001703057
Cusip
Exchange
NASDAQ Global Select
Full Time Employees
475
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2020-12-11
Address
2215 Yukon Street
City
Vancouver
State
BC
Country
CA
Zip
V5Y 0A1
Phone
604 559 9005
All financial data provided by FMP